Clinical Performance of Habitual Wearers of Avaira Toric When Refitted With Clariti Toric Lenses
Launched by COOPERVISION, INC. · Sep 24, 2014
Trial Information
Current as of April 25, 2025
Completed
Keywords
ClinConnect Summary
This is a 30-subject, prospective dispensing study comparing the clinical performance of the subjects' habitual Avaira toric lenses following a refit with Clariti toric lenses. Subject's habitual Avaira toric lenses will be evaluated at the first visit and then re-fitted with a pair of Clariti toric lenses for 1 month of daily wear. After the dispensing visit, subjects will return for evaluations at 1 week, 2 weeks and 4 weeks.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Is between 18 and 40 years of age (inclusive)
- • Has had a self-reported visual exam in the last two years
- • Is an adapted Avaira toric contact lens (CL) wearer (at least 1 week of wear in Avaira toric)
- • Has a contact lens spherical prescription between +6.00 to - 8.00 (inclusive)
- • Have no less than 0.75D of astigmatism and no more than 1.75 D in both eyes.
- • Can achieve best corrected spectacle distance visual acuity of 20/25 (0.10 logMAR) or better in each eye.
- • Can achieve a distance visual acuity of 20/30 (0.18 logMAR) or better in each eye with the study contact lenses.
- • Has clear corneas and no active ocular disease
- • Has read, understood and signed the information consent letter.
- • Patient contact lens refraction should fit within the available parameters of the study lenses.
- • Is willing to comply with the wear schedule (at least 5 days per week, \> 8 hours/day assuming there are no contraindications for doing so).
- • Is willing to comply with the visit schedule
- Exclusion Criteria:
- • Is not a habitual wearer of Avaira toric lenses
- • Has a CL prescription outside the range of the available parameters of the study lenses.
- • Has a spectacle cylinder less than -0.75D or more than -1.75 D of cylinder in either eye.
- • Has a history of not achieving comfortable CL wear (5 days per week; \> 8 hours/day)
- • Has contact lens best corrected distance vision worse than 20/25 (0.10 logMAR) in either eye.
- • Presence of clinically significant (grade 2-4) anterior segment abnormalities
- • Presence of ocular or systemic disease or need of medications which might interfere with contact lens wear.
- * Slit lamp findings that would contraindicate contact lens wear such as:
- • Pathological dry eye or associated findings
- • Pterygium, pinguecula, or corneal scars within the visual axis
- • Neovascularization \> 0.75 mm in from of the limbus
- • Giant papillary conjunctivitis (GCP) worse than grade 1
- • Anterior uveitis or iritis (past or present)
- • Seborrheic eczema, Seborrheic conjunctivitis
- • History of corneal ulcers or fungal infections
- • Poor personal hygiene
- • Has a known history of corneal hypoesthesia (reduced corneal sensitivity)
- • Has aphakia, keratoconus or a highly irregular cornea.
- • Has Presbyopia or has dependence on spectacles for near work over the contact lenses.
- • Has undergone corneal refractive surgery.
- • Is participating in any other type of eye related clinical or research study.
About Coopervision, Inc.
CooperVision, Inc. is a global leader in the contact lens industry, dedicated to advancing the science of vision care through innovative products and clinical research. With a commitment to enhancing the quality of life for millions of wearers worldwide, the company specializes in developing a diverse range of contact lenses, including those for myopia control, astigmatism, and presbyopia. CooperVision actively engages in clinical trials to ensure the safety, efficacy, and comfort of its products, while also contributing to the broader understanding of eye health and vision correction. By fostering partnerships with healthcare professionals and researchers, CooperVision aims to drive advancements in vision care and provide exceptional solutions that meet the evolving needs of eye care practitioners and their patients.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Valencia, , Spain
Patients applied
Trial Officials
Robert Montés-Mico, OD
Principal Investigator
Optometry Research Group (GIO)
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials